{
    "medicine_id": "33644b0f682b4abb1ef2d5fd39cb07995b053914",
    "platform_id": "DB12366",
    "metadata": {
        "name": "Mepsevii 2 mg 1mL Injection",
        "composition": "2 mg 1mL Vestronidase alfa",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII MPS VII Sly syndrome",
            "contraindications": {
                "disease": "Treatment of vestronidase alfa with doses up to 20 mg kg administered weekly in rats did not result in adverse effect on fertility and reproductive performance of male and female rats Studies assessing the mutagenic or carcinogenic potential of vestronidase alfa have not been performed FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In all patients evaluated MEPSEVII treatment resulted in reduction of urinary excretion of GAGs including chondroitin sulfate and dermatan sulfate which was sustained with continued treatment FDA Label",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}